Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet
Pressmeddelande

ChemoTech Expands in Illinois as 8th Clinic within Major U.S. Veterinary Group Adopts TSE Technology

Scandinavian ChemoTech

Scandinavian ChemoTech AB today announced that its veterinary subsidiary, VQ Animal Care Inc., has secured a new partnership in Illinois. With this latest order, the eighth clinic within one of the largest U.S. veterinary groups has now decided to implement the company's Tumor Specific Electroporation (TSE)-underscoring the accelerating nationwide adoption of ChemoTech's innovative oncology solution.
 

Expanding Options in Veterinary Oncology
An Illinois-based clinic has introduced ChemoTech's advanced Tumor Specific Electroporation (TSE) therapy-a minimally invasive treatment that enhances the impact of low-dose chemotherapy through gentle, dynamic electrical pulses. This patented approach gives veterinarians a powerful new tool for managing tumors while reducing damage to healthy tissue. For pets, the therapy offers shorter recovery times, fewer side effects, lower recurrence rates, and an improved quality of life.
 

Illinois: A Key Market for Oncology Pet Healthcare

Illinois is home to more than 12.5 million residents and a diverse community of pet owners. Approximately 48.6% of Illinois households own a pet. Nationally, about 44.5% of households own dogs and nearly 29% own cats, underscoring the importance of expanding advanced oncology treatment for small companion animals.

 

Danny Nesrallah, Head of Business Development North America at VQ Animal Care Inc. said:

"TSE often reduces the total cost of care by being less invasive, causing less tissue destruction, and requiring less aftercare. For clinics, it improves efficacy while lowering side effects and reducing follow-up care demands-enhancing the overall experience for both patients and their families. We are proud to see vetIQure™ TSE adopted by an eighth clinic within one of the largest veterinary groups in the United States. This milestone shows the growing trust in our technology and its potential to transform oncology care for pets."

 

 

 

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.